A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
EDG-5506 is an investigational product intended to protect and improve function of dystrophic
muscle fibers. This Phase 1 study of EDG-5506 will assess the safety, tolerability, and
pharmacokinetics (PK) and of EDG-5506 in adult healthy volunteers and in adults with Becker
muscular dystrophy (BMD).